TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02496676

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium L-threonate
Description: In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium L-threonate
Description: In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) magnesium sulfate (MgSO4)
Description: In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous (IV) magnesium sulfate (MgSO4)
Description: In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
Study: NCT02671162

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wheat
Description: 3 times a day each time 2 capsules before eating meal for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaria
Description: 3 times a day each time 2 capsules before eating meal for 8 weeks.
Study: NCT01374035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Description: A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
Study: NCT04074915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test group
Description: Chamomile mouth rinse
Study: NCT01471041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous Window Needle Guide
Description: Subcutaneous, extravascular needle guide made of medical-grade titanium
Study: NCT03614884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling and Smoking Treatment
Description: The treatment condition will have access to 7 treatment modules on content surrounding both gambling and smoking behaviours. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling and smoking behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially. Participants in this condition will also be provided with nicotine replacement therapy (NRT) in the form of nicotine patches to use for the duration of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling only treatment
Description: The control condition will have access to 7 treatment modules on content surrounding gambling only. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
Study: NCT00450320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
Study: NCT03905590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periapical surgery with amniotic membrane
Description: periapical surgery will be done followed by amniotic membrane placement over the defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery without amniotic membrane
Description: periapical surgery will be done without placement of membrane over the defect.
Study: NCT01253122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0037
Study: NCT06035822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing with TeamGAINS
Description: The IG debriefings were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool, using this tool as a debriefing script, in accordance with the objectives Clinical Simulation Scenario
Study: NCT03420534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone 1 MG
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iloperidone 1 MG
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
Study: NCT01662284

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
Study: NCT03420534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fasting
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: postprandial
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: postprandial
Description: An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
Study: NCT01662284

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Intervention type: DRUG
Intervention: 124I-NM404
Description: 124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
Study: NCT04468503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two differnt protien prescription (ig per kg per day and 2g per kg /day )will be assigned to each group interventional
Description: In this study intervention will be the dose of protein, one group will be prescribed with the protein dose (1 g/kg/day) and other group will be on prescribed higher dose (2gm/kg/day) of protein according to the ASPEN guideline for critically ill and the energy requirements (other than proteins) will be 25 kcal/kg of adjusted body weight (Picolo et al.,). Each subject in the trail will provide remaining medical nutrition therapy according to the therapeutic guidelines in the field. The medical nutrition management other than protein will be adjust according to need of each patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two differnt protien prescription (ig per kg per day and 2g per kg /day )will be assigned to each group interventional
Description: In this study intervention will be the dose of protein, one group will be prescribed with the protein dose (1 g/kg/day) and other group will be on prescribed higher dose (2gm/kg/day) of protein according to the ASPEN guideline for critically ill and the energy requirements (other than proteins) will be 25 kcal/kg of adjusted body weight (Picolo et al.,). Each subject in the trail will provide remaining medical nutrition therapy according to the therapeutic guidelines in the field. The medical nutrition management other than protein will be adjust according to need of each patient.
Study: NCT03226054

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Modifications
Description: Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
Study: NCT01038947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uricase-PEG 20
Description: Intramuscular injection of Uricase-PEG 20 without premedication
Study: NCT00978302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
Study: NCT00873301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vestibulectomy
Description: Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
Study: NCT01910727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Together on Diabetes-Hopkins
Description: The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
Study: NCT03669094

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius V4II-90
Description: 7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1\*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
Study: NCT01542190

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: ketorolac tromethamine 0.4%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: ketorolac tromethamine 0.4%
Study: NCT00029198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage
Description: 15 massage given tid

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham massage
Description: non-massage touch
Study: NCT03669094

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
Study: NCT03119025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous DC-vaccines
Description: Patients will be vaccinated via intracutaneous injection of autologous DCs (5×106) combined with adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU).~Initiating course: one vaccination per week, during 1 month. Maintaining course: one vaccination per month, during 6 month. Patients will be monitored in a 2 months (after completing of initiating course), 7 months (after completing of maintaining course) and 13 months (in a 6 months post-vaccination follow-up).
Study: NCT01498003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban
Description: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
Study: NCT00978302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Intradermal injection at time of biopsy and again 24 h later
Study: NCT02595034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and Benzoyl Peroxide Gel 1%5%
Description: Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BenzaClin® Topical Gel
Description: BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Study: NCT02649101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide tablet 100mg qn po.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice chemotherapy
Description: Investigators will declare no constraint of regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physician's choice chemotherapy
Description: Investigators will declare no constraint of regimens.
Study: NCT00499109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: DV Group: 35 mg/m\^2 on days 1 and 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.
Study: NCT04992988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
Study: NCT01700829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
Study: NCT03160729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: pre-operative, single-shot injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: pre-operative, single-shot injection
Study: NCT01152606

Intervention type: DRUG
Intervention: trastuzumab [Herceptin]
Description: There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
Study: NCT01498003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline solution
Description: same use as tirofiban
Study: NCT01518660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Bi-weekly progressive resistance training
Study: NCT01280149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P
Description: injections of substance P and low dose allergen or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: substance P
Description: injections of substance P and low dose allergen or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P
Description: injections of substance P and low dose allergen or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P
Description: injections of substance P and low dose allergen or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P
Description: injections of substance P and low dose allergen or placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: substance P
Description: injections of substance P and low dose allergen or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P injections
Description: injections of substance P for 8 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: substance P injections
Description: injections of substance P for 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P injections
Description: injections of substance P for 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P injections
Description: injections of substance P for 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: substance P injections
Description: injections of substance P for 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: substance P injections
Description: injections of substance P for 8 weeks
Study: NCT04567147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients received the formula probiotic for consecutive 8 weeks ( one sachet per day ).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).